{"DataElement":{"publicId":"4552571","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 4 Week Cytotoxic Chemotherapy 8 Week Alemtuzumab Occurrence Yes No Not Applicable Indicator","preferredDefinition":"Text term to signify whether at least four weeks have passed since a patient received cytotoxic systemic chemotherapy, or at least eight weeks have passed since alemutuzumab was received by a patient between the documentation of relapse/progressive disease and enrollment into a clinical trial.","longName":"WSH_4WK_8WK_AGT_IND","context":"CITN","contextVersion":"1","DataElementConcept":{"publicId":"4571613","version":"1","preferredName":"Washout Period Progressive Disease Relapse To Enrollment Adverse Event Recovery Greater Than or Equal 4 Week Cytotoxic Chemotherapy 8 Week Alemtuzumab Occurrence","preferredDefinition":"A period of time to allow one agent to clear the body before another agent can be safely introduced.  Washout periods vary depending on the agents involved._Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure._Cancer that is increasing in scope or severity._Used as a function word to indicate direction, purpose, or movement._The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled._A healing process and/or an outcome implying relative health._A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways._A number with no fractional part, including the negative and positive numbers as well as zero.::4_Any period of seven consecutive days._Anticancer drugs that kill cells, especially cancer cells.A number with no fractional part, including the negative and positive numbers as well as zero.::8_Any period of seven consecutive days._A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)_An instance of something happening, such as an event or incident.","longName":"4571571v1.0:4571611v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"4571571","version":"1","preferredName":"Washout Period Adverse Event Progressive Disease To Enrollment Recovery","preferredDefinition":"A period of time to allow one agent to clear the body before another agent can be safely introduced.  Washout periods vary depending on the agents involved.:Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure.  Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with another drug(s) or procedure(s).:Cancer that is increasing in scope or severity.:Used as a function word to indicate direction, purpose, or movement.:The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled.:A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.","longName":"4571571v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Washout Period","conceptCode":"C42872","definition":"A period of time to allow one agent to clear the body before another agent can be safely introduced.  Washout periods vary depending on the agents involved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"To","conceptCode":"C65107","definition":"Used as a function word to indicate direction, purpose, or movement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Enrollment","conceptCode":"C37948","definition":"The act of registration, entering in a list, catalog, group, study; also, the number of subjects enrolled.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recovery","conceptCode":"C25746","definition":"A healing process and/or an outcome implying relative health.  The term is typically used in the context of direct and indirect effects of sickness or injury.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07095D68-95A8-7517-E050-BB89AD436CD7","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"ONEDATA","dateModified":"2014-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4571611","version":"1","preferredName":"Greater Than or Equal To Integer::4 Week Cytotoxic Chemotherapy Integer::8 Week Alemtuzumab Occurrence","preferredDefinition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.:A number with no fractional part, including the negative and positive numbers as well as zero.::4:Any period of seven consecutive days.:Anticancer drugs that kill cells, especially cancer cells.:A number with no fractional part, including the negative and positive numbers as well as zero.::8:Any period of seven consecutive days.:A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04):An instance of something happening, such as an event or incident.","longName":"4571611v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Greater Than or Equal To","conceptCode":"C61583","definition":"A statement about the relative size or order of two objects specifying that either both objects are the same in quantity or measure or value or status or that the object of interest exceeds the other object in one of these ways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Cytotoxic Chemotherapy","conceptCode":"C15681","definition":"A drug therapy that is used to destroy cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Week","conceptCode":"C29844","definition":"Any period of seven consecutive days.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Occurrence","conceptCode":"C25275","definition":"An instance of something happening, such as an event or incident.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0709A1B3-30B1-0975-E050-BB89AD430D53","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"ONEDATA","dateModified":"2014-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0709A1B3-30C2-0975-E050-BB89AD430D53","latestVersionIndicator":"Yes","beginDate":"2014-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-11-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"4/18/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506036","version":"1","preferredName":"Yes No Not Applicable Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"YES_NO_NA_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"14","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not Applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3261243","version":"1","preferredName":"Not Applicable","longName":"3261243","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA2BBD66-6581-A6F2-E040-BB89AD4311D3","latestVersionIndicator":"Yes","beginDate":"2011-08-10","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-08-10","modifiedBy":"RAGUNATHANU","dateModified":"2024-02-05","changeDescription":"12/15/15 added N/A as alternate VM-tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-759A-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75A4-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-7590-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-757C-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ZHANGWE","dateModified":"2019-01-24","changeDescription":"3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. 8/3/2015 Corrections made to VD in order to restore to original format: removed C49486 as rep term and replaced with C49797; restored long name and definition per Dianne Reeves/tt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5999742","version":"1","longName":"CRF CDEs","context":"CITN","ClassificationSchemeItems":[{"publicId":"5999747","version":"1","longName":"Eligibility CDEs","context":"CITN"}]}],"AlternateNames":[{"name":"WSH_4WK_8WK_AGT_IND","type":"USED_BY","context":"CITN"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":">=4 weeks for systemic cytoto","type":"Preferred Question Text","description":">=4 weeks for systemic cytotoxic anticancer agents, anticancer investigation agents that are not defined as immunotherapy, or for tumor-targeting monoclonal antibodies (mAbs)with the exception of alemutuzumab for which the washout is at least 8 weeks","url":null,"context":"CITN"},{"name":"CITN-1","type":"Alternate Question Text","description":">=4 weeks from the last dose of systemic cytotoxic anticancer agents (>=6 weeks from the last dose of nitrosoureas or mitomycin C), anticancer investigational agents that are not defined as immunotherapy, or for tumor-targeting monoclonal antibodies (mAbs), with the exception of alemutuzumab for which the wash-out period must be at least 24 weeks.","url":null,"context":"CITN"},{"name":"CRF Text 3","type":"Alternate Question Text","description":"Will the required washout period of at least 4 weeks prior to the anticipated start date of study treatment be followed?","url":null,"context":"NRG"},{"name":"CRF Text 4","type":"Alternate Question Text","description":"Will the required washout period of 5 weeks prior to the anticipated start date of study treatment for enzalutamide or phenobarbital and 4 weeks prior to the anticipated start date of study treatment for all other agents be followed?","url":null,"context":"NRG"},{"name":"CITN-2","type":"Alternate Question Text","description":">= 4 weeks from the last dose of systemic cytotoxic anticancer agents (â‰¥6 weeks from the last dose of nitrosoureas or mitomycin C), anticancer investigational agents that are not defined as immunotherapy, or for tumor-targeting monoclonal antibodies (mAbs), with the exception of alemutzumab for which the wash-out period must be at least 16 weeks.","url":null,"context":"CITN"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"If yes, will the required washout period prior to starting study treatment of 2 weeks be completed?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0667E923-E999-933F-E050-BB89AD436428","latestVersionIndicator":"Yes","beginDate":"2014-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-27","modifiedBy":"VUJANOVA","dateModified":"2018-10-10","changeDescription":"4/15/16 Released, used in CITN-10. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}